, Volume 59, Issue 7, pp 665–675 | Cite as

Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging

  • Hyun Jung Yoon
  • Kook Jin Ahn
  • Song Lee
  • Jin Hee Jang
  • Hyun Seok Choi
  • So Lyung Jung
  • Bum Soo Kim
  • Shin Soo Jeun
  • Yong Kil Hong
Diagnostic Neuroradiology



The purposes of the present study are to assess whether different characteristics of oligodendrogliomas and astrocytic tumors are visible on MR imaging and to determine the added value of perfusion imaging in conventional MR imaging when differentiating oligodendrogliomas from astrocytic tumors.


We retrospectively studied 22 oligodendroglioma and 54 astrocytic tumor patients, including glioblastoma multiforme (GBM). The morphological tumor characteristics were evaluated using MR imaging. The rCBV, K trans, and V e values were recorded. All imaging and clinical values were compared. The ability to discriminate between the two entities was evaluated using receiver operating characteristic curve analyses. Separate comparison analysis between oligodendroglioma and astrocytic tumors excluding GBM was also performed.


The presence of calcification, higher cortex involvement ratio, and lower V e value were more representative of oligodendrogliomas than astrocytic tumors (P = <0.001, 0.038, and <0.001, respectively). The area under the curve (AUC) value of a combination of calcification and cortex involvement ratio was 0.796. The combination of all three parameters, including V e, further increased the diagnostic performance (AUC = 0.881). Comparison test of the two AUC areas revealed significant difference (P = 0.0474). The presence of calcification and higher cortex involvement ratio were the only findings suggestive of oligodendrogliomas than astrocytic tumors with exclusion of GBMs (P = 0.014 and <0.001, respectively).


Cortex involvement ratio and the presence of calcification with V e values were diagnostically accurate in identifying oligodendrogliomas. The V e value calculated from dynamic contrast-enhanced MR imaging could be a supportive tool for differentiating between oligodendrogliomas and astrocytic tumors including GBMs.


Oligodendroglioma Magnetic resonance imaging Dynamic contrast-enhanced MR imaging Ktrans Ve 


Compliance with ethical standards


No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Seoul St. Mary’s and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data.


  1. 1.
    Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the seer program, 1973-2001. Cancer 106(6):1358–1363CrossRefPubMedGoogle Scholar
  2. 2.
    Koeller KK, Rushing EJ (2005) From the archives of the AFIP: oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics 25(6):1669–1688CrossRefPubMedGoogle Scholar
  3. 3.
    McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 30(1):34–44CrossRefPubMedGoogle Scholar
  4. 4.
    Chinot O (2001) Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28(4 Suppl 13):13–18CrossRefPubMedGoogle Scholar
  5. 5.
    Perry A (2001) Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 8(4):183–199CrossRefPubMedGoogle Scholar
  6. 6.
    Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60(5):443–456CrossRefPubMedGoogle Scholar
  7. 7.
    Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in the CT/MR-era. Acta Neurochir 143(12):1195–1203CrossRefPubMedGoogle Scholar
  8. 8.
    Lee YY, Van Tassel P (1989) Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 152(2):361–369CrossRefPubMedGoogle Scholar
  9. 9.
    Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45(6):1279–1291 discussion 1191 CrossRefPubMedGoogle Scholar
  10. 10.
    Wu Z, Mittal S, Kish K, Yu Y, Hu J, Haacke EM (2009) Identification of calcification with MRI using susceptibility-weighted imaging: a case study. J Magn Reson Imaging 29(1):177–182CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ellenbogen JR, Walker C, Jenkinson MD (2015) Genetics and imaging of oligodendroglial tumors. CNS Oncol 4(5):307–315CrossRefPubMedGoogle Scholar
  12. 12.
    Jenkinson MD, Walker C, Brodbelt AR, Wilkins S, Husband D, Haylock B (2010) Molecular genetics, imaging and treatment of oligodendroglial tumours. Acta Neurochir 152(11):1815–1825CrossRefPubMedGoogle Scholar
  13. 13.
    Spampinato MV, Smith JK, Kwock L et al (2007) Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 188(1):204–212CrossRefPubMedGoogle Scholar
  14. 14.
    Arevalo-Perez J, Kebede AA, Peck KK et al (2015) Dynamic contrast-enhanced MRI in low-grade versus anaplastic oligodendrogliomas. J NeuroimagingGoogle Scholar
  15. 15.
    Li X, Zhu Y, Kang H et al (2015) Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. Cancer Imaging 15:4CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Saito T, Yamasaki F, Kajiwara Y et al (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81(8):1863–1869CrossRefPubMedGoogle Scholar
  17. 17.
    Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26(2):266–273PubMedGoogle Scholar
  18. 18.
    Chawla S, Krejza J, Vossough A et al (2013) Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol 34(8):1542–1549CrossRefPubMedGoogle Scholar
  19. 19.
    Fellah S, Caudal D, De Paula AM et al (2013) Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 34(7):1326–1333CrossRefPubMedGoogle Scholar
  20. 20.
    Emblem KE, Scheie D, Due-Tonnessen P et al (2008) Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 29(9):1664–1670CrossRefPubMedGoogle Scholar
  21. 21.
    Kapoor GS, Gocke TA, Chawla S et al (2009) Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neuro-Oncol 92(3):373–386CrossRefGoogle Scholar
  22. 22.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMedGoogle Scholar
  23. 23.
  24. 24.
    Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):223–232CrossRefPubMedGoogle Scholar
  25. 25.
    Paldino MJ, Barboriak DP (2009) Fundamentals of quantitative dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am 17(2):277–289CrossRefPubMedGoogle Scholar
  26. 26.
    Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27(4):859–867PubMedGoogle Scholar
  27. 27.
    Jung SC, Yeom JA, Kim JH et al (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 35(6):1103–1110CrossRefPubMedGoogle Scholar
  28. 28.
    Yun TJ, Park CK, Kim TM et al (2015) Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 274(3):830–840CrossRefPubMedGoogle Scholar
  29. 29.
    Tietze A, Mouridsen K, Mikkelsen IK (2015) The impact of reliable prebolus T 1 measurements or a fixed T 1 value in the assessment of glioma patients with dynamic contrast enhancing MRI. Neuroradiology 57(6):561–572CrossRefPubMedGoogle Scholar
  30. 30.
    DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMedGoogle Scholar
  31. 31.
    Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7):1442–1448CrossRefPubMedGoogle Scholar
  32. 32.
    Vonofakos D, Marcu H, Hacker H (1979) Oligodendrogliomas: CT patterns with emphasis on features indicating malignancy. J Comput Assist Tomogr 3(6):783–788CrossRefPubMedGoogle Scholar
  33. 33.
    Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A (1999) The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neuro-Oncol 44(2):99–107CrossRefGoogle Scholar
  34. 34.
    Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25(2):214–221PubMedGoogle Scholar
  35. 35.
    Narang J, Jain R, Scarpace L et al (2011) Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors. J Neuro-Oncol 102(2):287–293CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Hyun Jung Yoon
    • 1
    • 2
  • Kook Jin Ahn
    • 2
  • Song Lee
    • 2
  • Jin Hee Jang
    • 2
  • Hyun Seok Choi
    • 2
  • So Lyung Jung
    • 2
  • Bum Soo Kim
    • 2
  • Shin Soo Jeun
    • 3
  • Yong Kil Hong
    • 3
  1. 1.Department of Radiology and Center for Imaging ScienceSamsung Medical Center, Sungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Radiology, College of MedicineSeoul St. Mary’s Hospital, The Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Department of Neurosurgery, College of MedicineSeoul St. Mary’s Hospital, The Catholic University of KoreaSeoulRepublic of Korea

Personalised recommendations